StockNews.com lowered shares of Anika Therapeutics (NASDAQ:ANIK – Free Report) from a buy rating to a hold rating in a report issued on Monday.
Separately, Barrington Research cut their target price on Anika Therapeutics from $37.00 to $25.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st.
Check Out Our Latest Stock Report on ANIK
Anika Therapeutics Price Performance
Anika Therapeutics (NASDAQ:ANIK – Get Free Report) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.24). Anika Therapeutics had a negative net margin of 59.40% and a negative return on equity of 2.22%. The business had revenue of $41.92 million during the quarter, compared to analyst estimates of $39.90 million. During the same period in the previous year, the company earned ($0.06) earnings per share. As a group, research analysts predict that Anika Therapeutics will post -0.1 earnings per share for the current year.
Institutional Investors Weigh In On Anika Therapeutics
Institutional investors have recently made changes to their positions in the company. Eastern Bank bought a new stake in shares of Anika Therapeutics in the 3rd quarter valued at approximately $28,000. Quest Partners LLC increased its holdings in shares of Anika Therapeutics by 115.8% in the 3rd quarter. Quest Partners LLC now owns 6,904 shares of the biotechnology company’s stock valued at $171,000 after acquiring an additional 3,705 shares during the last quarter. Lazard Asset Management LLC bought a new stake in shares of Anika Therapeutics in the 1st quarter valued at approximately $180,000. State Board of Administration of Florida Retirement System bought a new stake in shares of Anika Therapeutics in the 1st quarter valued at approximately $198,000. Finally, Atria Investments Inc bought a new stake in shares of Anika Therapeutics in the 3rd quarter valued at approximately $218,000. 91.53% of the stock is currently owned by institutional investors.
About Anika Therapeutics
Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.
Further Reading
- Five stocks we like better than Anika Therapeutics
- Dividend Payout Ratio Calculator
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- Where Do I Find 52-Week Highs and Lows?
- Breakout Alert: Qualcomm Just Hit The Rally Button
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.